FDA to Discuss Ban on Menthol in Tobacco Products

Dec.30.2022
FDA to Discuss Ban on Menthol in Tobacco Products
FDA to hold workshop on banning menthol flavor in tobacco products on January 12, 2023.

On January 12, 2023, the US Food and Drug Administration (FDA) will hold a workshop on the ban of flavored tobacco products, specifically regarding the use of menthol as a flavoring in tobacco products. The proposed tobacco product standard is to "prohibit the use of menthol as a characterizing flavor in cigarettes and cigars on a scientific basis," marking the first tobacco-related workshop of 2023.


The FDA presentation will provide scientific evidence to inform the development of these proposed regulations and explain the highly impactful scientific assessments used by the FDA to review them.


Bridget Ambrose, the Director of Population Health Science at the FDA's Center for Tobacco Products (CTP) Office of Science (OS), will be delivering a speech. Ambrose has over 20 years of experience in tobacco control and regulatory science, and has expertise in longitudinal analyses of tobacco use.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts “Decisive 2026” Concludes: Reviewing the 2025 U.S. Market and Mapping Compliance Pathways Ahead
2Firsts “Decisive 2026” Concludes: Reviewing the 2025 U.S. Market and Mapping Compliance Pathways Ahead
2Firsts hosted “Decisive 2026” in Shenzhen, bringing together industry perspectives to examine major shifts in the U.S. new tobacco market in 2025 and their global implications. Sessions covered U.S. market dynamics, technical insights from recently PMTA-authorized products, an investor lens on tobacco capital markets, and 2025 news/product highlights. The event underscored a structural shift from “gray business” toward compliance and sustainable growth, expected to become clearer by 2026.
Jan.09
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
According to KT&G’s official website (Feb 5, 2026), KT&G released its 2025 fourth-quarter and full-year results. Driven by strong growth in its overseas cigarette business and a rebound in its real estate business, the company posted double-digit increases in both revenue and operating profit, reaching record-high performance.
Feb.05 by 2FIRSTS.ai
UK Court Sentences Shrewsbury Retailer for Illegal Vape and Counterfeit Tobacco Sales
UK Court Sentences Shrewsbury Retailer for Illegal Vape and Counterfeit Tobacco Sales
A UK local authority has secured convictions against a Shrewsbury retailer and its former director for selling illegal disposable vapes, counterfeit tobacco and a nicotine vape to a minor, highlighting continued enforcement against non-compliant nicotine products.
Feb.05 by 2FIRSTS.ai
China’s Nov. Vape Exports to U.S. Hold at $549 Million, Sustaining High After October’s $591 Million Peak
China’s Nov. Vape Exports to U.S. Hold at $549 Million, Sustaining High After October’s $591 Million Peak
China’s Nov. vape exports to the U.S. held at $549 million, following October’s $591 million record. 2025 YTD exports reached $3.72 billion, officially eclipsing 2024’s full-year total. This $1.14 billion 60-day surge signals a critical inventory overhang, heightening financial and regulatory risks for manufacturers.
Dec.22
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS UK unveils 2026 pop-up events plan, first stops set for London and three other cities
IQOS’ UK website shows the company will roll out time-limited pop-up experience spaces across Britain in 2026 for adult consumers. The first confirmed locations are London, the West Midlands area near Birmingham, Manchester and Romford, offering product demonstrations, pop-up-only promotions and nicotine pouch sampling. Entry will be restricted to those aged 18 and over, with “Challenge 25” ID checks in place.
Feb.03 by 2FIRSTS.ai